Ocugen, Inc. Common Stock (OCGN) Stock Price

OCGNStock

$1.32+25.71%52W

Market Cap$447.63M

P/E—

PEG Ratio—

Div yield—

Beta2.22

OCGN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-37.77%

Price vs S&P 500 (4W)4.06%

VGM Score35.70

Book Value / Share (Quarterly)$0.02

P/TBV (Annual)1.94x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)366.28%

Cash Flow / Share (Quarterly)$-0.18

Price vs S&P 500 (YTD)-15.04%

Net Profit Margin (TTM)-1343.08%

EPS (TTM)$-0.20

10-Day Avg Trading Volume3.38M

EPS Excl Extra (TTM)$-0.20

EPS (Annual)$-0.23

ROI (Annual)-92.71%

Net Profit Margin (5Y Avg)-119113.09%

Cash / Share (Quarterly)$0.30

Revenue Growth QoQ (YoY)8.38%

ROA (Last FY)-155.91%

Revenue Growth TTM (YoY)0.40%

EBITD / Share (TTM)$-0.16

ROE (5Y Avg)-119.32%

Operating Margin (TTM)-1137.46%

Cash Flow / Share (Annual)$-0.18

P/B Ratio78.86x

P/B Ratio (Quarterly)102.24x

Net Income / Employee (Annual)$-584,900

EV / Revenue (TTM)92.57x

Net Interest Coverage (TTM)-14.90x

ROA (TTM)-80.57%

EPS Incl Extra (Annual)$-0.23

Current Ratio (Annual)1.06x

Quick Ratio (Quarterly)0.75x

3-Month Avg Trading Volume6.59M

52-Week Price Return25.71%

Revenue / Employee (TTM)$41,100

Tangible BV / Share (Quarterly)$45.33

P/S Ratio (Annual)103.74x

Asset Turnover (Annual)0.10x

52-Week High$2.73

Operating Margin (5Y Avg)-45112.35%

EPS Excl Extra (Annual)$-0.23

CapEx CAGR (5Y)-9.81%

26-Week Price Return-25.84%

Quick Ratio (Annual)0.81x

13-Week Price Return-6.38%

Total Debt / Equity (Annual)0.97x

Current Ratio (Quarterly)0.80x

Enterprise Value$441.86M

Asset Turnover (TTM)0.06x

Book Value / Share Growth (5Y)-13.42%

Revenue / Employee (Annual)$38,000

Pretax Margin (Annual)-1537.41%

Cash / Share (Annual)$0.06

3-Month Return Std Dev61.67%

Net Income / Employee (TTM)$-552,600

ROE (Last FY)-182.42%

Net Interest Coverage (Annual)-6.75x

EPS Basic Excl Extra (Annual)$-0.23

Total Debt / Equity (Quarterly)5.03x

EPS Incl Extra (TTM)$-0.20

ROI (TTM)-165.19%

P/S Ratio (TTM)95.91x

Pretax Margin (5Y Avg)-63113.09%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$45.33

Price vs S&P 500 (52W)7.16%

Year-to-Date Return-2.22%

5-Day Price Return-2.94%

EPS Normalized (Annual)$-0.23

ROA (5Y Avg)-89.86%

Net Profit Margin (Annual)-1537.41%

Month-to-Date Return7.32%

Cash Flow / Share (TTM)$-0.32

EBITD / Share (Annual)$-0.20

Operating Margin (Annual)-1425.70%

LT Debt / Equity (Annual)0.92x

ROI (5Y Avg)-96.85%

LT Debt / Equity (Quarterly)4.17x

EPS Basic Excl Extra (TTM)$-0.20

P/TBV (Quarterly)1.94x

P/B Ratio (Annual)7.91x

Pretax Margin (TTM)-1343.08%

Book Value / Share (Annual)$0.10

Price vs S&P 500 (13W)-8.34%

Beta2.22x

Revenue / Share (TTM)$0.01

ROE (TTM)-1306.71%

52-Week Low$1.00

vGradeF

gGradeC

mGradeC

vgmGradeD

OCGN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.05	-$0.06	-16.92%(-$0.01)
Q1 2026	May 5, 2026	-$0.05	-$0.06	-15.38%(-$0.01)
Q4 2025	Mar 4, 2026	-$0.06	-$0.06	-4.35%(-$0.00)
Q3 2025	Nov 5, 2025	-$0.06	-$0.07	-21.74%(-$0.01)
Q2 2025	Aug 1, 2025	-$0.06	-$0.05	+11.77%(+$0.01)

OCGN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.15

4.17

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
OCGNOcugen, Inc. Common Stock	F	C	C	$1.32
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Ocugen, Inc. Common Stock

Ocugen Inc develops gene therapies, cell therapies, and vaccines targeting unmet medical needs across multiple therapeutic areas. The company's primary focus is on retinal diseases, including inherited conditions such as retinitis pigmentosa and Leber congenital amaurosis, as well as age-related diseases including dry age-related macular degeneration and geographic atrophy. Its pipeline includes modifier gene therapy, novel biologics, regenerative medicine cell therapies, and inhaled mucosal vaccine platforms.